NewswireToday - /newswire/ -
London, United Kingdom, 2008/07/24 - New analysis from Frost & Sullivan, European Drug Delivery Market-Opportunity Analysis, finds that the European pulmonary drug delivery market earned revenues of $7.00 billion in 2007 and estimates this to reach $12.94 billion in 2014.
The demand for novel drug delivery systems is rising and pharmaceutical companies have been involved in developing innovative new methods. Impending patent expirations will stimulate a surge in novel drug delivery methods for existing products, while sophisticated reformulation will generate substantial revenues in the European pharmaceutical market.
New analysis from Frost & Sullivan (pharma.frost.com), European Drug Delivery Market-Opportunity Analysis, finds that the European pulmonary drug delivery market earned revenues of $7.00 billion in 2007 and estimates this to reach $12.94 billion in 2014. The analysis also finds that the European transdermal drug delivery market earned revenues of $4.04 billion in 2007 and estimates this to reach $7.87 billion in 2014.
"Drug delivery is a fast growing and highly dynamic segment of the pharmaceutical and biotechnology industry," notes Frost & Sullivan Industry Analyst Sylvia Miriyam Findlay. "Various factors have contributed to the growth of this area, including the poor efficacies of certain drugs, patent expirations and the urgent need for life cycle management facing drugs nearing patent expiry."
However, pharmaceutical companies are looking to enhance the safety record of their products by introducing novel drug delivery technologies. This will also boost their competitive edge and enable them to maximise revenue generation.
The foremost challenge presented by the pulmonary route of drug delivery is the inability to deliver drugs directly to the alveoli. In addition, large molecules do not permeate the skin barrier and hence, fail to be delivered by the transdermal method. Ineffective drug delivery presents a significant technological challenge to market expansion.
"Market participants should focus on developing novel technologies that support the passage of large peptides," notes Findlay. "This will be critical to sustaining market growth, as the pharmaceutical/biotechnology industry is moving towards monoclonal antibody (Mab) therapeutics. Mabs, which are large peptides, are already being used in various therapeutic applications."
If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the European drug delivery market-opportunity analysis, then send an email to Patrick Cairns, Corporate Communications, at pcairns_pr[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.
European Drug Delivery Market-Opportunity Analysis is part of the Pharmaceutical and Clinical Diagnostics Growth Partnership Service Programme, which also includes research in the following markets: European Fibromyalgia Market and European Growth Hormone Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.
European Drug Delivery Market – Opportunity Analysis